|
| Evidence map analysis of clinical research on treatment of heart failure with preserved ejection fraction with proprietary Chinese medicines |
| Hits 222 Download times 59 Received:December 04, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2026.02.08 |
| Key Words
proprietary Chinese medicines;heart failure with preserved ejection fraction;evidence map;clinical study;methodological quality assessment |
| Author Name | Affiliation | E-mail | | LIU Chunqiu | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China | | | QU Huiyan | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Shuguang Anhui Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Hefei 230031, China | | | YIN Fangyi | Laogang Community Health Service Center, Shanghai 201302, China | | | LI Chuyi | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China | | | LIU Qian | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China | | | LI Tianshu | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China | | | ZHOU Hua | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Shuguang Anhui Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Hefei 230031, China | zhouhua@shutcm.edu.cn |
|
| Abstract
|
| [Objective]The aim of this study was to synthesize and analyze existing clinical studies on proprietary Chinese medicines for the treatment of heart failure with preserved ejection fraction(HFpEF)by constructing an evidence map. The validity and limitations of the existing evidence were systematically assessed to provide a scientific basis for subsequent clinical studies.[Methods]Seven databases were systematically searched, all with a search timeframe from the establishment of the database to May 2025, to evaluate the clinical study characteristics and methodological quality of the included literature.[Results]Finally, 177 literatures were included, including 166 interventional studies, 10 secondary studies, and 1 expert consensus. Thirty-five proprietary Chinese medicines were involved, with Qili Qiangxin Capsules being the most widely used. Most of the studies had a period of 2 weeks to 4 weeks and a sample size of 51~100 cases. Most trial groups were often combined with Western medicine. The main outcome indicators include total effective rate, cardiac function indicators, safety indicators. Regarding the evaluation of methodological quality, randomized controlled trials had bias in randomization and measurement of endpoint indicators, and were at risk of selective reporting. Meta-analysis, on the other hand, reported inadequacies in the registration of study protocols, enumeration of the list of excluded literature, and disclosure of conflicts of interest, with fewer evaluation indicators for reticulation Meta-analysis, and large variations in the results between different literatures. The expert consensus was evaluated as recommended after revision. It recommended five proprietary Chinese medicines, which currently have a low level of evidence.[Conclusion]The quality of clinical research evidence on proprietary Chinese medicines for HFpEF needs to be improved. There is an urgent need for large-sample, long-period randomized controlled trials to further deepen the association between evidence and efficacy. In order to provide more evidence-based and clinical practice protocols for traditional Chinese medicine treatment of HFpEF. |
|
|
|
|
|
|
|
